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Introduction 
The term amyloidosis describes a large group of hereditary or acquired rare conditions 
caused by the extracellular deposition of insoluble amyloid fibrils composed of misfolded 
proteins, which leads to a loss of the normal architecture and function of the involved tissues and 
organs.
1
 These disorders can be due to many proteins,
1
 but the fibrillary deposits share distinctive 
structural and tinctorial properties: namely, an amorphous eosinophilic appearance under light 
microscopy using routine histological stains; an “apple-green” birefringence after Congo-red 
staining under a polarized light microscope (Figure 1); presence of rigid nonbranching fibrils 
7.5–10 nm in diameter on electron microscopy; and a predominantly antiparallel β-sheet 
secondary structure visible under infrared and X-ray diffraction.
1
 Amyloidoses are classified 
according to the protein composition of the fibrils and by the clinical features of the disease. 
The most common types of systemic amyloidosis associated with a clinically relevant 
cardiac involvement include AL amyloidosis and the transthyretin (TTR)-related forms. AL 
(where A stands for amyloidosis and L for light-chains) is due clonal plasma cells in the bone 
marrow producing an abnormal amount of circulating immunoglobulin free light chains, which 
are responsible of the fibrillary deposits.
2
 The incidence of AL is uncertain, but is thought to be 6 
to 10 new cases/year per million population in the United Kingdom and United States. This type 
of amyloidosis is a rapidly progressive disease that affects multiple organs, including the heart in 
50% of patients. The prognosis of patients with AL amyloidosis is poor when heart failure is 
present, with a median survival of 5 months from diagnosis. Transthyretin is a protein mainly 
produced by the liver, which transports thyroxin and retinol binding protein, and can lead to two 
distinct forms of amyloidosis.  The hereditary, TTR-related form (ATTRm) can be caused by 
over 100 point-mutations of TTR. The clinical spectrum of ATTRm varies widely from an 
exclusively neurologic involvement to a predominantly cardiac presentation. This heterogeneity 
is linked to several factors including specific TTR variants, patient and transmitting parent 
gender, geographic distribution and endemic vs. non-endemic aggregation type.
3
 On the 
contrary, wild-type TTR-related amyloidosis (ATTRwt, also known as systemic “senile” 
amyloidosis or SSA), in which the TTR amino acid sequence is normal, almost exclusively 
affects the hearts of elderly men.
2,3
 In all these main etiologic subtypes of the disease, the 
presence of cardiac involvement is a well-known negative prognostic factor.
2
 
4 
 
Intramyocardial amyloid infiltration leads to a progressive increase of ventricular wall 
thickness and stiffness of the heart.
1,2
 
 
Echocardiography is the most widely used non-invasive test in patients with heart failure or 
abnormal cardiac findings on examination. Patients with amyloidosis may have significant 
cardiac abnormalities, several of which are highly suggestive of the disease.
2,3
 
Echocardiographically, amyloidotic cardiomyopathy (AC) is defined by left ventricular (LV) 
wall thickness > 12 mm in the absence of any other plausible causes of LV hypertrophy. Figure 
2a shows representative echocardiographic findings in AC, including biventricular wall 
thickening, an increased thickness of the interatrial septum and of the valve leaflets, mild 
pericardial effusion.  
The diagnosis of cardiac amyloidosis is challenging and relies on a high degree of clinical 
suspicion. When AC is an isolated disorder or when the cardiac manifestations of a multi-organ 
involvement predominate, the correct recognition of the disease can be difficult since it can 
mimic other more common causes of true LV hypertrophy, including hypertrophic 
cardiomyopathy (HCM) and hypertensive heart disease (HHD).
2-5
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Aims 
Although a definite diagnosis of AC is largely based on imaging modalities ―in 
particular cardiac magnetic resonance and echocardiography― and tissue biopsy, ECG remains a 
first-line diagnostic test essential in prompting the diagnostic suspicion. Characteristic 
electrocardiography tracing from patients with AC (Figure 2b) show low QRS voltage in the 
limb leads, ‘pseudo-infarction’ patterns, and T-wave abnormalities that resemble ischemia. 
However, even if the importance of the ECG at this level has been pointed out for a long time, 
the suggested ECG diagnostic signs rely on a few studies, each including a limited number of 
patients mainly with AL amyloidosis.
6,7
 without any gender distinction and  validated cut off. 
TTR-related AC, which can mimic other cardiomyopathies more frequently than AL, has been 
much less focused on.
4 
Furthermore, the control groups in these studies mainly included patients 
with secondary LV hypertrophy or even without LV hypertrophy.
8-10
 
We aimed to assess and validate the diagnostic value of ECG for non-invasive identification of 
AC in a clinical setting of patients with increased LV wall thickness due to a large spectrum of 
conditions, including AL and TTR-related amyloidosis, HCM and HHD.  
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Methods 
Clinical setting and study design 
We conducted a multicenter retrospective study based on data pooled from two large 
Italian referral Centers for the diagnosis and management of systemic amyloidosis (Bologna and 
Pavia) and hypertrophic cardiomyopathy (Bologna). Since 1990 these Centers provide 
coordinated amyloidosis networks involving neurology, cardiology, haematology and 
nephrology services, genetic research groups, and liver/heart transplantation programs.  
All consecutive patients with echocardiographically defined AC and genetically/biopsy proven 
amyloidosis due to AL, ATTRm or ATTRwt evaluated at our Centres between 1990 and 
December 2012 were enrolled. Exclusion criteria included: coexistent, more than mild, 
pericardial effusion and clinical history of coronary artery disease.  
For comparison, we included patients with genetically proven (or familial) HCM (defined 
below) from the cardiomyopathies clinic at Bologna Center and patients with HHD (defined 
below) included in the database of our Echocardiographic Labs in the same period.  
Exclusion criteria for the control groups were: coexistent, more than mild, pericardial effusion; 
clinical history of coronary artery disease; concomitant hematologic diseases including the 
monoclonal gammopathy of undetermined significance; apical HCM; end-stage evolution of 
HCM.
11
 
We reviewed the clinical, electrocardiographic and echocardiographic data of the three 
groups at the time of their first evaluation at either Center.  
To assess the diagnostic performance of all proposed indices, a first analysis was conducted in 
the first 469 consecutive patients, who presented at our centers and who were diagnosed with 
either AC of the different etiologies, or HHD or HCM. We analyzed and compared the 
diagnostic performance of different indexes for the identification of AC, separately for females 
and males. We included in the analysis low QRS voltage as a pure ECG marker of cardiac 
amyloidosis, as well as the presence of symmetric LV hypertrophy as an isolated 
echocardiographic marker of an infiltrative phenotype. In addition to these indices, we evaluated 
the diagnostic performance of previously described and new indexes combining electrical 
(electrocardiographic) and anatomical (echocardiographic) mass:  
1. Low QRS voltage (QRS amplitude ≤0.5 mV in all limb leads or ≤ 1 mV in all precordial 
leads); 
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2. Presence of symmetric LV hypertrophy, defined as a ratio between the end-diastolic 
thickness of the interventricular septum and of the LV posterior wall was less than 1.3. 
3. Sokolow index (sum of S wave in lead V1 and R wave in lead V5 or V6) divided by the 
cross-sectional area (CSA) of the LV wall, where CSA was calculated according to Carroll 
JD et al: CSA = (π()*((LV end-diastolic diameter/20)+mean LV wall thickness/10)^2-
π()*(LV end-diastolic diameter/20)^2)/body surface area, (mm/cm2/m2);8 
4. Low QRS voltage in combination with interventricular septal thickness >1.98 cm, according 
to Rahman et al;
9
 
5. Sokolow index divided by LV mass indexed to body surface area (LVMI), (mm/(g/m2));  
6. Sokolow index divided by LV wall thickness 
7. Sokolow divided by LV wall thickness indexed to height^2.7 (mm/m2.7) 
8. Peripheral QRS score (sum of QRS voltages in the limb leads) divided by LVMI 
(mV/(g/m
2
));  
9. Peripheral QRS score divided by LV wall thickness (mV/mm); 
10. Peripheral QRS score divided by LV wall thickness indexed to height2.7, (mV/(mm/m2.7)), 
11. Total QRS score (sum of QRS voltages in the limb and precordial leads) divided by LVMI 
(mV/(g/m
2
)); 
12. Total QRS score divided by LV wall thickness (mV/mm); 
13. Total QRS score divided by LV wall thickness indexed to height2.7 (mV/(mm/m2.7)); 
 
We tested these indexes in the following settings, which represent the most common scenarios in 
the clinical practice:  
- Identification of AC due to AL, ATTRm or ATTRwt vs. other causes of LV hypertrophy 
(HCM and HHD);  
- Identification of AC due to AL, ATTRm or ATTRwt vs. HCM;  
- Identification of AL-related AC vs. other causes of LV hypertrophy (HCM and HHD);  
- Identification of AL-related AC vs. HCM; 
- Identification of TTR-related AC (either ATTRm or ATTRwt) vs. other causes of LV 
hypertrophy (HCM and HHD);  
- Identification of TTR-related AC (either ATTRm or ATTRwt) vs. HCM. 
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For the continuous indices we generated separated cut-off values for males and females of for the 
identification of AC in the different settings. Indexes associated with the best diagnostic 
performances were then tested in a second group of 298 consecutive patients with either AC, 
HHD or HCM. 
At presentation, all patients provided informed consent for anonymous publication of 
scientific data. In our country, formal ethical approval was not applicable for this observational 
retrospective study involving only routinely performed procedures performed during the 
diagnostic work-up. 
 
Diagnostic definitions 
Amyloidosis and amyloidotic cardiomyopathy (AC). Diagnosis of amyloidosis was 
defined by histological documentation of Congo-red staining and apple-green birefringence 
under cross-polarized light in at least one involved organ.
12 
AC was echocardiographically 
defined as end-diastolic thickness of the interventricular septum >1.2 cm in the absence of any 
other plausible causes of ventricular hypertrophy.
2,13
 
Clear-cut distinction between TTR-related and AL amyloidosis was based on genotyping 
and/or immunohistochemistry.
2,14
 Diagnosis of ATTRm was defined by a documented 
transthyretin mutation at DNA analysis following procedures described elsewhere;
15
 ATTRwt by 
positive immunohistochemistry for TTR (at endomyocardial biopsy (EMB)) in the absence of 
TTR mutation at DNA analysis;
16
 AL by presence of monoclonal plasma cells at bone marrow 
biopsy, in absence of both immunostaining for TTR and TTR mutation at DNA analysis.
17,18
 
Hypertrophic cardiomyopathy (HCM). Diagnosis of HCM was based on an 
echocardiographic maximal LV wall thickness >13 mm in any myocardial segment, or a 
septal/posterior wall thickness ratio >1.3 in normotensive patients, or a septal/posterior wall 
thickness ratio >1.5 in hypertensive patients,
19,20
 after an accurate and extensive work-up 
including molecular genetics, pedigree construction, cardiac magnetic resonance, 
99m
TC-DPD 
scintigraphy,
21
 and EMB in selected cases. Only patients with genetically proven sarcomeric 
HCM or with a clear family history of HCM were included in the study. 
Hypertensive heart disease (HHD). Clinical diagnosis of HHD was based on the 
presence of LV hypertrophy at echocardiography (mean LV wall thickness >11 mm) in patients 
with long-standing history of arterial hypertension on antihypertensive therapy, in the absence of 
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other plausible causes of LV hypertrophy after an accurate and extensive work-up including 
molecular genetics, pedigree construction, cardiac magnetic resonance, 
99m
TC-DPD scintigraphy, 
and EMB in selected cases.  
 
Instrumental definitions. 
ECG and echocardiographic measurements were based on the standard definitions.
22,23
  
 ECG. Abnormal ECG was defined as presenting of one or more of the following features: 
conduction disturbances (atrioventricular block, right bundle branch block, left bundle branch 
block, left anterior or posterior hemiblock), low QRS voltages (QRS amplitude ≤0.5 mV in all 
limb leads or ≤1 mV in all precordial leads), ST and T wave abnormalities and ‘pseudo-
infarction’ pattern (pathological Q waves, in absence of coronary artery disease). 
 Echocardiography. Echocardiograms were analyzed for the following characteristics: 
interventricular septal thickness, posterior wall thickness, LVMI, LV end-diastolic diameter, 
atrial size, overall LV ejection fraction (calculated with the Simpson method).
23,24
 LV mass was 
calculated according to the Devereux method and classified as ‘increased’ when >130g/m2 in 
men and >110 g/m
2
 in women.
25
  
 
Statistical analysis. 
 Summary statistics were expressed as median [interquartile range] or numbers 
(percentages). Independence of categorical variables was tested using Fisher's exact test or 
Pearson's chi-square test. Independence of continuous variables was tested using Mann-Whitney 
U test or Kruskal-Wallis test. For multiple comparisons we calculated Bonferroni-adjusted p 
values. Spearman’s rank correlation coefficient (rho) was used to study the possible correlation 
between total QRS score and LVMI.  
 Receiver operator characteristic (ROC) curves were constructed to determine separate 
cut-off values for males and females of the different ECG/echocardiographic derived indexes for 
the identification of cardiac amyloidosis in the different subsets derived from a population of 469 
consecutive patients. Sensitivity, specificity, positive (LR+) and negative (LR-) likelihood ratios 
were calculated. The indices associated with the best diagnostic performance were then tested in 
a second group of 298 consecutive patients. Finally, we performed a cumulative analysis 
10 
 
including the whole cohort of 767 consecutive patients. Analyses were conducted using STATA 
11.2 SE. P values <0.05 were considered significant.  
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Results 
 
Study population and instrumental findings. 
The main analysis included 469 patients: 262 patients with AC (AL, n=161; ATTRm, 
n=71; ATTRwt, n=30), and 106 with HCM and 101 with HHD, respectively, as control group.  
The validation group included 298 patients: 62 with AC (AL, n=30; ATTRm, n=17; ATTRwt, 
n=15), 67 with HCM, and 169 with HHD. 
Amyloidosis was histologically documented in each case with AL (abdominal fat biopsy 
in 237 cases, EMB in 72 cases, other biopsies in the remaining 20 cases) or ATTRwt (EMB in all 
45 cases). Among the 88 patients with ATTRm, EMB was performed in 63. In the remaining 25 
cases the diagnosis was based on molecular genetics and on the typical echocardiographic 
pattern in absence of other plausible causes of LV “hypertrophy” after an extensive work up 
including cardiac magnetic resonance and 
99m
Tc-DPD scintigraphy in selected cases. 
Among the 173 patients with HCM, sarcomere gene mutations were searched for in 117 
patients and found in 80: MYBPC3 in 52 cases, TNNT2 in 5, MYH7 in 7, TNNI3 in 2. Double 
mutations were found in 14 patients (MYBPC3-MYH7 in 8 cases, MYBPC3-TNNT2 in 2, 
MYBPC3-TNNI3 in 2, MYBPC3-TPM1 in 2). All the other gene negative cases included in the 
study had a clear family history of HCM. EMB was performed, for clinical reasons, in 10 
patients (without sarcomeric mutations) to exclude infiltrative or storage diseases. We excluded 
70 HCM patients evaluated during the same period with end-stage (n=38) or apical (n=20) 
forms, or with associated coronary artery disease or equivocal diagnosis (n=12).  
EMB was performed in 13 of the 270 patients with a final diagnosis of HHD and ruled 
out infiltrative/storage diseases in all cases. We excluded 20 patients evaluated during the same 
period due to an associated coronary artery disease or absence of the clinical / laboratory 
information needed for ruling out infiltrative/storage diseases. 
 
Table 1 summarizes the main clinical and echocardiographic characteristics of the 
consecutive 469 patients included in the main analysis, according to the etiological subgroups. 
As expected, hypertensive patients were the oldest; male gender was predominant in all three 
subgroups, with 90% prevalence in ATTRwt. AC patients showed more frequently a severe heart 
failure (NYHA class III/IV) at presentation. On echocardiogram, LV wall thickness was greater 
12 
 
in patients with HCM and with AC. LV “hypertrophy” was generally more asymmetric in HCM 
and concentric in the other groups. LV ejection fraction was around the lower normal limits in 
AC, normal in HHD and “supernormal” in HCM. Left atrium was, on average, larger in AC and 
in HCM than in HHD. 
Table 2 summarizes the main ECG findings and the combined ECG/echocardiographic 
(ECG/ECHO) indexes in the three groups of patients. Patients with AC and HCM more 
frequently showed abnormal ECGs. A low voltage pattern was more frequent in AC than in the 
other groups (with the highest prevalence in AL-related amyloidosis). Pseudo-infarct pattern was 
more frequent in AC than in HCM, whereas abnormally negative T waves were predominant in 
HCM. All the ECG/ECHO indexes were significantly higher in HCM patients than in HHD and 
AC (p<0.001). 
 
Diagnostic performance of ECG for the identification of cardiac amyloidosis. 
In order to assess the diagnostic performance of the ECG/ECHO indexes for the 
identification of AC among patients with increased LV wall thickness, ROC curves were 
constructed to identify the best cut-off values for each combined ECG/ECHO index in males and 
females (figure 3a and 3b).  
Table 3 summarizes the diagnostic performance (sensitivity, specificity, positive and 
negative likelihood ratios) associated with the analyzed ECG, ECHO and combined ECG/ECHO 
indices for the identification of AC in the overall population and in selected subcategories, 
among males (3a) and females (3b).  
As expected, both among males and females, low QRS voltage on ECG showed high 
specificity and low sensitivity in all clinical contexts. On the contrary, a symmetric LV 
hypertrophy showed a good sensitivity but poor specificity, which increased when comparing 
AC and HCM. Compared to the isolated indices, all those combining ECG/ECHO indices 
showed a higher diagnostic performance for the identification of AC.  
 Among males, the combined ECG/ECHO index previously proposed by Rahman et al
9
 
was associated with a lower diagnostic performance than expected, while the one by Carrol et al
8
 
was characterized by an average diagnostic performance, comparable to Sokolow index/LVMI 
ratio, but however lower than other combined indices (including peripheral QRS score/LVMI, 
peripheral QRS score/LV wall thickness, total QRS score/LVMI, total QRS score/LV wall 
13 
 
thickness and total QRS score/LV wall thickness indexed to height
2.7
). Total QRS score divided 
by LV wall thickness indexed to height^2.7 provided the best overall diagnostic performance in 
the overall cohort and in the different subgroups, with an AUC (figure 2a) significantly higher 
than that of Sokolow index divided by CSA of LV wall (p=0.006),
8
 but not significantly higher 
than that of peripheral QRS score divided by LVMI (p=0.25). 
 Among females, we observed a lower diagnostic performance for all the indices, likely 
due to a smaller sample size. However, the index proposed by Rahman
9 
resulted particularly 
specific in differentiating AC from other causes of LVH, even when considering only TTR 
patients. The best diagnostic performance was reached by peripheral QRS score/LVMI, 
peripheral QRS score/LV wall thickness indexed to height
2.7
, total QRS score/LVMI, total QRS 
score/LV wall thickness and total QRS score/LV wall thickness indexed to height^2.7, which did 
not result significantly different when considering the AUC associated to the different indices in 
the ROC curves (figure 2b). 
We tested the indices associated with the best diagnostic performance in 200 males (21 
AL, 12 ATTRm, 10 ATTRwt, 46 HCM, 111 HHD) and 98 females (9 AL, 5 ATTRm, 5 
ATTRwt, 21 HCM, 58 HHD). Table 4 summarizes the diagnostic performance (sensitivity, 
specificity, positive and negative likelihood ratios) associated with the selected indices in males 
(4a) and females (4b), finding similar results as described in the main analysis of 469 patients. 
We therefore performed a cumulative analysis including the whole cohort of consecutive 
767 patients and generated diagnostic performances associated with the different indices 
analyzed, which can be found in table 5a and 5b, according to the gender.  
Overall, among males, total QRS score divided by LV wall thickness indexed to 
heaight^2.7 turned out to be the one associated with the best diagnostic performance (table 5a). 
Among females, the best diagnostic performance was associated with total QRS score/ LV wall 
thickness and total QRS score divided by LV wall thickness indexed to height^2.7, although with 
no statistical significance with respect to the other combined indices, likely due to a lack of 
power. 
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Discussion 
Our study ─which included the largest series so far of patients with biopsy/genetically-
proven AC─ shows that simple indices combining ECG and echocardiographic variables (such 
as total QRS divided by LVMI or LVWT) can help in identifying AC within a population with 
increased LV wall thickness due to different etiologies, including AL and TTR-related 
amyloidoses, HCM and HHD.  
Despite the great development that imaging modalities have achieved in the past years for the 
non-invasive diagnosis of cardiac amyloidosis, the role of ECG remains fundamental, mainly in 
the first steps of the diagnostic work-up (table 5).
6-10,26-28
 Indeed, in order to submit patients to 
second and third level investigations (including magnetic resonance and EMB) a high 
preliminary suspicion is necessary and can only be prompted by a widely available (and 
inexpensive) tool, such as ECG. 
Since the late-sixties low QRS voltage has been considered the mainstay for ECG 
diagnosis of cardiac amyloidosis.
29,30
 Prevalence of low QRS voltage was 46% among 127 
patients with biopsy-proven AL-related cardiac amyloidosis studied by Murtagh et al.
7 
A similar 
prevalence (45%) was recently reported by Cheng et al in a small series of 11 patients with AL 
amyloidosis
10 
and by Hoignè et al (40%) in a group of 15 cases with non-etiologically defined 
cardiac amyloidosis.
26
 The low QRS prevalence was higher (70-74%) in a larger series with AL 
cardiac amyloidosis studied by Dubrey et al
6 
and in a group of 58 patients with cardiac 
amyloidosis of different etiologies studied by Rahman et al (56%).
9
A recent study from our 
groups questioned the diagnostic role of low QRS voltage by itself, highlighting the effect of the 
etiology of amyloidosis in the heterogeneity of electrocardiographic manifestations.
31
 Indeed, in 
this large cohort of 233 patients with biopsy-proven cardiac amyloidosis including 33% with 
mutant or wild-type TTR-related disease, we found low QRS voltage in 60% of AL patients as 
compared with only 25% and 40% in the ATTRm and ATTRwt subgroups, respectively 
(p<0.001).
31
 The present study confirms, in a larger population, the elusive role of low QRS 
voltage by itself for the diagnosis of AC, and the high reliance of this variable on the etiology of 
amyloidosis. In fact, low QRS voltage was present in 62% of AL patients but only in 24% and 
27% of ATTRm and ATTRwt patients respectively (p=<0.001). Interestingly, low QRS voltage 
was also present in 20% of our control group with hypertensive heart disease, probably due to 
extensive myocardial fibrosis in a longstanding condition. Consequently, both specificity and 
15 
 
sensitivity of this finding for the diagnosis of AC resulted suboptimal, especially when patients 
with non-AL related AC were considered (Tables 3-5).   
In recent years, two seminal albeit small studies
8,10
 shifted the focus from low QRS 
voltage by itself to the relation between QRS voltage and LV wall thickness and showed that in 
AL amyloidosis this relationship appears to be peculiar and distinctive. We tried to overcome the 
limitations of the previous studies, extending the analyses to a large series of patients with 
biopsy-proven amyloidosis due to different etiologies. We also selected our control groups very 
carefully, including patients with HCM and genetically-proven diagnosis or family history of 
HCM, and patients with systemic hypertension, all of whom displaying HHD.   
In our AC population the relation between QRS voltage and LV mass appears quite distinctive 
regardless of the amyloidosis subtype. The practical consequence of this type of relationship is 
the possibility of using a simple index combining ECG and echocardiographic variables as a 
non-invasive first-line diagnostic tool. This index (total QRS score divided by LV wall 
thickness) consists of a simple ratio between the arithmetic ─not algebraic─ sum of the QRS 
complexes in peripheral and precordial leads and the LV wall thickness measured on two-
dimensional echocardiogram. Both sensitivity and specificity of this index are high in both males 
and females, and superior to the previously proposed tests (Sokolow index divided by the cross-
sectional area of the LV wall
8 
and low QRS voltage in combination with interventricular septal 
thickness >1.98 cm (Tables 3-5 and Figure 3).
9 
Notably, our index allows an accurate 
identification, not only of AL-related cardiomyopathy, but also of hereditary TTR amyloidosis 
and ATTRwt. 
Alongside low QRS voltage and voltage/mass relationship, our study highlights the high 
frequency of electrocardiographic findings mimicking coronary artery disease (pseudo-infarction 
and abnormal ST-T waves) regardless of AC etiology and the relatively high frequency of left 
bundle branch block in ATTRwt (Table 2). 
Although our study was not aimed to investigate the electro-genetic mechanisms of ECG 
abnormalities in cardiac amyloidosis, some insights can stem from our data. Both low QRS 
voltages and pseudo-infarction patterns have been traditionally interpreted as secondary to the 
interstitial amyloid deposition leading to electrical “attenuation”. This phenomenon, however, 
cannot explain all our findings by itself. Indeed, the inverse correlation between voltage and 
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mass in AC is decidedly weak. Other mechanisms, including direct cellular toxic damage and 
loss or atrophy of myocardial cells could therefore be involved. 
 
Limitations 
 Our results derive from a retrospective analysis of patients with a high prevalence of AC. 
Although both sensitivity and specificity of our combined indices are particularly high (the 
highest among all previously proposed tests), their predictive value in a real world population 
with unexplained LV hypertrophy is not known. For instance, given the +LR and –LR (Tables 5) 
associated with total QRS divided by LV wall thickness (indexed or not to height^2.7 depending 
on gender), the positive and negative predictive value of this test in our setting (where the overall 
prevalence of AC was 44% among males and 39% among females) are 76% and 82% among 
males, and 72% and 84%, respectively. If we assume a disease prevalence around 1%, the post-
test probability of AC in a male patient with a total QRS score divided by LV wall thickness 
indexed to height^2.7 < 36.4 would be more than tripled, but around 4%. On the other hand, the 
post-test probability in a male patient with total QRS score divided by LV wall thickness indexed 
to height^2.7 > 36.4 would be < 0.3%. This observation underlines the importance of a global 
approach to the diagnostic work-up of AC, which should not consider the ECG alone but 
organically, along with the other tools including the clinical evaluation, echocardiography, 
magnetic resonance and scintigraphy.  
Designing this study we intentionally considered only patients with definite cardiomyopathies or 
overt LV hypertrophy. Thus, our results could not be generalized to cases with initial forms of 
cardiac amyloidosis or mild HHD, for which dedicated studies should be conducted.  
 
Conclusions.  
In cardiac amyloidosis the peculiar relationship between QRS voltages and LV mass is a 
hallmark of the disease. In patients with increased LV wall thickness, AC can be accurately 
suspected by a single non-invasive index combining ECG and echocardiographic findings. Total 
QRS score/LV wall thickness provides the best diagnostic performance across a wide range of 
disease subtypes including different etiologies of AC, HCM and HHD.  
17 
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Figure legends 
Figure 1. Histological findings from an endomyocardial biopsy of a heart infiltrated by amyloid: 
in the left panel the amyloid deposits (in pale pink after staining with hematoxylin-eosin) appear 
as an amorphous/homogeneous substance that diffusely infiltrates the myocardium, leading to an 
anatomical and functional isolation of single cells or groups of myocytes. The typical “apple-
green” birefringence (in the right panel) can be appreciated after Congo-red staining under a 
polarized light microscope. 
Figure 2. Characteristic echocardiographic (a) and electrocardiographic (b) findings from a 
patient with amyloidotic cardiomyopathy (AC) owing to hereditary transthyretin amyloidosis. 
Echocardiographically, a diffuse thickening is apparent in the interventricular septum, posterior 
left ventricular wall, anterior right ventricular wall and interatrial septum, associated with a 
sparkle appearance of the ventricular myocardium. In the apical view (bottom left) mitral valve 
leaflet leaflets look thickened as well. The small, coexisting pericardial effusion is typical. The 
typical electrocardiographic pattern include low QRS voltages, ‘pseudo-infarction’ pattern, and 
diffuse T-wave abnormalities that might resemble ischemia. 
Figure 3. ROC curves of the ECG/echocardiographic derived indexes for the diagnosis of 
amyloidotic cardiomyopathy vs. other causes of left ventricular (LV) hypertrophy (hypertrophic 
cardiomyopathy and hypertensive heart disease), in the main analysis including 460 consecutive 
patients. The area under the curve (AUC) for each index is reported for each index. Among 
males (3a), the AUC of total QRS score divided by LV wall thickness indexed to height^2.7 
(Total QRS/(LVWT/h
2.7
)) was significantly higher than that of Sokolow index divided by the 
CSA of LV wall (Carrol index in the figure, p=0.006) but not higher than that of the peripheral 
QRS score divided by LVMI (Peripheral QRS/LVMI in the figure, p=0.25). Among females 
(3b), the AUC of peripheral QRS score divided by LV wall thickness indexed to height^2.7 
(peripheral QRS/(LVWT/h
2.7
)) and total QRS score divided by LV wall thickness indexed to 
height^2.7 (Total QRS/(LVWT/h
2.7
)) were the highest, but not significantly higher than that of 
peripheral QRS score divided by LVMI (Peripheral QRS/LVMI in the figure, p=0.42 and 0.63, 
respectively) or of the Sokolow index divided by the CSA of LV wall (Carrol index in the figure, 
p=0.17 and 0.14, respectively).  
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Table 1. Main clinical and echocardiographic characteristics of the different subgroups of 
patients. 
 AC 
(n=262) 
HCM 
(n=106) 
HHD 
(n=101) 
Adjusted  
p values** 
 Overall  
(n=262) 
AL 
(n=161) 
ATTRm 
(n=71) 
ATTRwt 
(n=30) 
   
Age, years  
(mean±SD) 
62 
[53-69] 
62 
[53-69] 
53 
[45-63] 
78 
[73-80] 
59  
[50-70] 
72 
[63-79] 
<0.001†‡ 
Male gender, n (%) 182 (72) 101 (63) 54 (76) 27 (90) 71 (66) 61 (60)  0.008 * 
NYHA class III-IV, n 
(%) 
86 (33) 60 (4) 14 (20) 12 (40) 10 (9) 0 (0) <0.001*† 
LV-EDD, mm 
(median[IQR]) 
45 
[41-49] 
44 
[40-49] 
46 
[42-50] 
46 
[42-52] 
43  
[38-46] 
46 
[42-49] 
<0.001*‡ 
 
IVSd, mm  
(median[IQR]) 
16 
[14-18] 
16 
[14-17] 
16 
[14-19] 
18 
[15-21] 
18  
[15-21] 
13 
[12-13] 
<0.001*†‡ 
PWd, mm 
(median[IQR]) 
15 
[13-17] 
14 
[13-16] 
15 
[13-18] 
15 
[14-19] 
12 
[10-18] 
12 
[12-12] 
<0.001*† 
Mean LVWT, mm 
(median[IQR]) 
16 
[14-18] 
15 
[14-17] 
16 
[14-19] 
17 
[15-19] 
15 
[14-18] 
13 
[12-13] 
<0.001†‡ 
Symmetric LVH, n (%) 236 (90) 143 (89) 67 (94) 26 (87) 45 (42) 96 (95) <0.001†‡ 
LVMI, g/m
2
 
(median[IQR]) 
185 
[148-227] 
175 
[144-213] 
194 
[149-248] 
233 
[171-282] 
165 
[139-223] 
135 
[121-152] 
<0.001†‡ 
LV-EF, % 
(median[IQR]) 
55  
[45-64] 
55 
[43-64] 
57 
[50-65] 
50 
[40-60] 
73 
[67-78] 
66 
[62-70] 
<0.001*†‡ 
LA diameter, mm 
(median[IQR]) 
46  
[40-51] 
46 
[40-50] 
44 
[40-48] 
51 
[44-56] 
45 
[40-49] 
43 
[40-48] 
<0.02† 
**p values were adjusted according to Bonferroni method and refer to the comparison between 
AC (overall population), HCM and HHD.  
p <0.05 at post-hoc analysis: *AC vs HCM; † AC vs HHD; ‡ HCM vs HHD. 
AC=amyloidotic cardiomyopathy; AL=light-chains-related amyloidosis; ATTRm=hereditary 
transthyretin-related amyloidosis; ATTRwt=wild-type transthyretin-related amyloidosis; 
HCM=hypertrophic cardiomyopathy; HHD=hypertensive heart disease; LV=left ventricular; 
IQR=interquartile range; LV-EDD=LV end diastolic diameter; IVSd=interventricular septum in 
diastole; PWd=LV posterior wall in diastole; LVWT=LV wall thickness; LVH=LV hypertrophy; 
LVMI=body surface area indexed LV mass; LV-EF=LV ejection fraction; LA=left atrium. 
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Table 2. ECG findings and combined ECG/echocardiographic indexes in the different subgroups 
of patients. 
 AC 
(n=262) 
HCM 
(n=106) 
HHD 
(n=101) 
P** 
 Overall 
(n=262) 
AL 
(n=161) 
ATTRm 
(n=71) 
ATTRwt 
(n=30) 
   
Normal ECG, n (%) 14 (5) 6 (4) 7 (10) 1 (3) 5 (5) 42 (42) <0.001†‡ 
AF, n (%) 30 (11) 19 (12) 3 (4) 8 (27) 8 (8) 20 (20)  0,022 ‡ 
Low QRS voltage, n 
(%) 
125 (48) 100 (62) 17 (24) 8 (27) 6 (6) 21 (21) <0.001*†‡ 
LVH (Sokolow index 
≥ 35 mm), n (%) 
9 (3) 4 (2) 3 (4) 2 (7) 30 (30) 5 (5) <0.001*‡ 
Peripheral QRS score,  
mV (median [IQR]) 
27  
[19-38] 
24 
[17-33] 
37 
[28-49] 
33 
[23-36] 
58 
[42-80] 
39 
[30-49] 
<0.001*†‡ 
Total QRS score, mV 
(median [IQR]) 
94  
[74-124] 
85 
[68-104] 
114 
[90-136] 
118 
[94-152] 
186 
[147-228] 
116 
[101-134] 
<0.001*†‡ 
LBBB, n (%) 21 (8) 6 (4) 6 (8) 9 (30) 7(7) 4 (4) 0.388  
I degree AV block, n 
(%) 
61/253 
(24) 
34/152 (22) 19 (27) 8 (27) 8 (8) 7 (7) <0.001*† 
Pseudoinfarct 
pattern, % 
147 (56) 86 (53) 39 (55) 20 (67) 40 (40) 5 (5) <0.001*†‡ 
“Ischemic 
abnormalities” 
(negative T waves), n 
(%) 
134 (51) 83 (52) 35 (49) 16 (53) 81 (80) 23 (23) <0.001*†‡ 
Sokolow index/CSA of 
the LV wall (8), 
median [IQR] 
0.9 
[0.6−1.2] 
0.8 
[0.5−1.2] 
1.1 
[0.8−1.4] 
1 
[0.7−1.4] 
1.7 
[1.2−2.6] 
1.4  
[1.1−2] 
<0.001*†‡ 
Low QRS 
voltage+IVSd >1.98 
cm;
9
 
18 (7) 14 (9) 2 (3) 2 (7) 0 (0) 0 (0) n.a. 
Sokolow index/LVMI, 
median [IQR] 
0.08 
[0.05−0.1] 
0.09 
[0.06−0.1] 
0.09 
[0.06−0.1] 
0.08 
[0.05−0.1] 
0.15 
[0.1−0.2] 
0.13 
[0.1−0.2] 
<0.001*† 
Sokolow 
index/LVWT, median 
[IQR] 
0.97  
[0.6-1.3] 
0.8 
[0.6-1.2] 
1.15  
[0.8-1.6] 
1.15 
[0.8-1.5] 
1.78 
[1.2-2.7] 
1.5 
[1.04-2.1] 
<0.001*†‡ 
Sokolow 
index/LVWT/h
2.7
, 
median [IQR] 
3.94 
[2.4-5.5] 
3.3 
[2.3-4.8] 
4.45 
[3.2-6.6] 
5.25 
[3.1-6.0] 
7.73 
[4.8-10.9] 
5.56 
[4.3-8.1] 
<0.001*†‡ 
Peripheral QRS 
score/LVMI, median 
[IQR] 
0.14 
[0.1−0.2] 
0.13 
[0.09−0.18] 
0.19 
[0.12−0.2] 
0.13 
[0.1−0.2] 
0.32 
[0.2−0.5] 
0.28 
[0.2−0.4] 
<0.001*†‡ 
Peripheral QRS 
score/LVWT, median 
[IQR] 
1.77 
[1.2-2.5] 
1.6 
[1.1-2.2] 
2.32 
[1.5-3.1] 
1.81 
[1.3-2.4] 
3.82 
[2.6-5.9] 
3.17 
[2.3-4.1] 
<0.001*†‡ 
Peripheral QRS score/ 
LVWT/h
2.7
, median 
[IQR] 
7.33 
[4.8-10.3] 
6.28 
[4.2-8.7] 
9.28 
[6.9-12.8] 
 
7.5 
[6.5-10.4] 
15.53 
[11.3-22.3] 
12.38 
[9.4-16.1] 
<0.001*†‡ 
Total QRS 
score/LVMI, median 
[IQR] 
0.5 
[0.4−0.7] 
0.5 
[0.4−0.6] 
0.6 
[0.4−0.8] 
0.5 
[0.4−0.6] 
1.0 
[0.8−1.4] 
0.8 
[0.7−1] 
<0.001*†‡ 
Total QRS 
score/LVWT, median 
6.2 
[4.6-7.9] 
5.7 
[4.3-7.04] 
7.08  
[5.7-8.8] 
7.11 
[5.5-8.4] 
12.1 
[9.1-16.7] 
9.21 
[7.8-10.5] 
<0.001*†‡ 
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[IQR] 
Total QRS 
score/LVWT/h
2.7
, 
median [IQR] 
25.6 
[18.2-
32.6] 
22.44 
[16.6-29.3] 
29.26 
[23.4-
37.0] 
28.57 
[23.3-
33.8] 
49.75 
[37.8-68-9] 
37.12 
[30.0-44.5] 
<0.001*†‡ 
**p values were adjusted according to Bonferroni method and refer to the comparison between 
AC (overall population), HCM and HHD.  
p <0.05 at post-hoc analysis: *AC vs HCM; † AC vs HHD; ‡ HCM vs HHD. 
AC=amyloidotic cardiomyopathy; AL=light-chains-related amyloidosis; ATTRm=hereditary 
transthyretin-related amyloidosis; ATTRwt=wild-type transthyretin-related amyloidosis; 
HCM=hypertrophic cardiomyopathy; HHD=hypertensive heart disease; IQR=interquartile range; 
AF=atrial fibrillation; LV=left ventricular; LVH=left ventricular hypertrophy; LBBB=left bundle 
branch block; AV=atrioventricular; CSA=cross sectional area; LVMI=body surface area indexed 
LV mass; n.a.=not applicable; IVSd=interventricual septum during diastole; LVWT=left 
ventricular wall thickness; h=height. 
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Table 3a. Diagnostic performance of the different indices for the identification of AC in the 
overall population and in selected clinical scenarios among males (n=314).  
 AC vs. other 
(HCM+HHD) 
AC vs. 
HCM 
AL vs. other 
(HCM+HHD) 
AL vs. 
HCM 
TTR vs. other 
(HCM+HHD) 
TTR vs. 
HCM 
Low QRS voltage on ECG 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
45.1% 
88.6%  
3.96 
0.6 
 
45.1%  
95.8% 
10.7 
0.6 
 
60.4% 
88.6%  
5.3 
0.4 
 
60.4% 
95.8% 
14.3 
0.4 
 
25.9% 
88.6%  
2.3 
0.8 
 
25.9% 
95.8% 
6.1 
0.8 
Symmetric LVH on ECHO 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
89.6% 
33.3% 
1.3 
0.3 
 
89.6% 
56.3% 
2.1 
0.2 
 
89.1% 
33.3% 
1.3 
0.3 
 
89.1% 
56.3% 
2.04 
0.2 
 
90.1% 
33.3% 
1.4 
0.3 
 
90.1% 
56.3% 
2.1 
0.2 
Sokolow index/CSA of LV wall (8)   
(cut off ≤ 1.2479) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
73.63% 
72.73% 
2.7 
0.4 
 
 
73.63% 
74.65% 
2.9 
0.3 
 
 
79.21% 
72.73% 
2.9 
0.3 
 
 
79.21% 
74.65% 
3.1 
0.3 
 
 
66.67% 
72.73% 
2.4 
0.5 
 
 
66.67%  
74.65% 
2.6 
0.4 
Low QRS voltage + IVSd >1.98 cm 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
45.1% 
88.6% 
3.9 
0.6 
 
45.1% 
95.8% 
10.7 
0.6 
 
60.4% 
88.6% 
5.3 
0.4 
 
60.4% 
95.8% 
14.3 
0.4 
 
25.9% 
88.6% 
2.3 
0.8 
 
25.9% 
95.8% 
6.1 
0.8 
Sokolow index/LVMI 
(cut off ≤ 0.1118881) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
75.27% 
70.45% 
2.6 
0.4 
 
 
75.27% 
69.01% 
2.2 
0.5 
 
 
81.19% 
70.45% 
2.7 
0.3 
 
 
81.19% 
69.01% 
2.6 
0.3 
 
 
67.90% 
70.45% 
2.3 
0.5 
 
 
67.90% 
69.01% 
2.2 
0.5 
Sokolow index/LVWT 
(cut off ≤ 1.230769) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
69.78% 
71.97%  
2.5 
0.4 
 
 
69.23% 
74.65% 
2.7 
0.4 
 
 
77.23%  
71.97%  
2.8 
0.3 
 
 
76.24% 
74.65% 
3.0 
0.3 
 
 
60.49% 
71.97% 
2.2 
0.5 
 
 
60.49% 
76.06% 
2.5 
0.5 
Sokolow index/(LVWT/h2.7) 
(cut off ≤ 5.49101) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
69.8% 
71.2% 
2.4 
0.4 
 
 
69.8% 
77.5% 
2.6 
0.3 
 
 
78.2% 
71.2% 
3.3 
0.4 
 
 
78.2% 
77.5% 
3.6 
0.3 
 
 
59.3% 
71.2%  
1.8 
0.5 
 
 
59.3% 
77.5% 
1.9 
0.7 
Peripheral QRS score/LVMI 
(cut off ≤ 0.205725) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
76.37% 
78.03% 
3.5 
0.3 
 
 
75.82% 
80.28% 
3.8 
0.3 
 
 
81.19% 
78.03% 
3.7 
0.2 
 
 
81.19% 
81.69% 
4.4 
0.2 
 
 
70.37% 
78.03% 
3.2 
0.4 
 
 
69.14% 
80.28% 
4.5 
0.3 
Peripheral QRS score/LVWT 
(cut off ≤ 2.37037) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
74.73% 
75.00% 
2.9 
0.3 
 
 
74.18% 
77.46% 
3.3 
0.3 
 
 
85.15% 
81.06% 
4.5 
0.2 
 
 
85.15% 
77.46% 
4.1 
0.3 
 
 
62.96% 
75.00% 
2.5 
0.5 
 
 
61.73% 
77.46% 
2.7 
0.5 
Peripheral QRS score/(LVWT/h2.7) 
(cut off ≤ 10.51418) 
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- Sensitivity 
- Specificity 
- LR+ 
- LR- 
74.2% 
76.5% 
2.9 
0.3 
74.2% 
78.9% 
3.05 
0.3 
81.2% 
76.5% 
4.1 
0.3 
81.2% 
78.9% 
4.2 
0.3 
65.4% 
76.5% 
2.2 
0.4 
65.4% 
78.9% 
2.3 
0.7 
Total QRS score/LVMI 
(cut off ≤ 0.7174721) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
80.22% 
81.06% 
4.2 
0.2 
 
 
80.22% 
83.10% 
4.7 
0.2 
 
 
85.15% 
81.06% 
4.5 
0.2 
 
 
85.15% 
83.10% 
5.0 
0.2 
 
 
74.07% 
81.06% 
3.9 
0.3 
 
 
74.07% 
83.10%    
4.4 
0.3 
Total QRS score/LVWT 
(cut off ≤ 8.357142) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
78.57% 
78.03% 
3.6 
0.3 
 
 
78.57% 
81.69% 
4.3 
0.3 
 
 
84.16% 
78.03% 
3.8 
0.2 
 
 
84.16% 
83.10% 
4.9 
0.2 
 
 
71.60% 
78.03% 
3.3 
0.4 
 
 
71.60% 
83.10% 
4.2 
0.3 
Total QRS score/(LVWT/h2.7) 
(cut off ≤ 36.40046) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
78.6% 
81.1%   
3.8 
0.2 
 
 
78.6% 
88.7% 
4.1 
0.1 
 
 
85.1% 
81.1% 
5.5 
0.2 
 
 
85.1% 
88.7% 
6 
0.1 
 
 
70.4% 
81.1% 
2.7 
0.3 
 
 
70.4% 
88.7% 
3 
0.2 
LR+ =positive likelihood ratio; LR- =negative likelihood ratio; AC=amyloidotic 
cardiomyopathy; HCM=hypertrophic cardiomyopathy; HHD=hypertensive heart disease; 
AL=light chain-related amyloidosis; CSA=cross sectional area; ED-IVS=end diastolic 
interventricular septum; LV=left ventricular; LVH=LV hypertrophy; LVMI=body surface area 
indexed LV mass; LVWT=LV wall thickness; h=height. 
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Table 3b. Diagnostic performance of the different indices for the identification of AC in the 
overall population and in selected clinical scenarios among females (n=155).  
 AC vs. other 
(HCM+HHD) 
AC vs. 
HCM 
AL vs. other 
(HCM+HHD) 
AL vs. 
HCM 
TTR vs. other 
(HCM+HHD) 
TTR vs. 
HCM 
Low QRS voltage on ECG 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
53.8% 
85.3% 
3.7 
0.5 
 
53.8% 
91.4% 
6.3 
0.5 
 
65% 
85.3% 
4.4 
0.4 
 
65% 
91.4% 
7.6   
0.4 
 
20% 
85.3% 
1.4 
0.9 
 
20% 
91.4% 
2.3 
0.9 
Symmetric LVH 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
91.3% 
29.3% 
1.3 
0.3 
 
91.3% 
60% 
2.3 
0.15 
 
88.3% 
29.3% 
1.3 
0.4 
 
88.3% 
60% 
2.2 
0.2 
 
100% 
29.3% 
1.4 
0 
 
100% 
60% 
2.5 
0 
Sokolow index/CSA of LV wall (8)  
(cut off ≤ 1.1753) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
68.75%  
69.33%  
2.3 
0.5 
 
 
67.50% 
71.43% 
2.4 
0.5 
 
 
75.00% 
69.33% 
2.4 
0.4 
 
 
73.33% 
71.43% 
2.6 
0.4 
 
 
50.00% 
69.33% 
1.6 
0.7 
 
 
45.00% 
71.43% 
1.6 
0.8 
Low QRS voltage + IVSd >1.98 cm 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
53.8% 
85.3% 
3.7 
0.5 
 
53.8% 
91.4% 
6.3 
0.5 
 
65% 
85.3% 
4.4 
0.4 
 
65% 
91.4% 
7.6 
0.4 
 
20% 
85.3% 
1.4 
0.9 
 
20% 
91.4% 
2.3 
0.9 
Sokolow index/LVMI 
(cut off ≤ 0.1055705) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
68.75% 
68.00% 
2.1 
0.5 
 
 
67.50% 
71.43% 
2.2 
0.4 
 
 
78.33% 
68.00% 
2.5 
0.3 
 
 
76.67% 
71.43% 
2.7 
0.3 
 
 
40.00% 
68.00%   
1.3 
0.9 
 
 
40.00% 
74.29% 
1.6 
0.8 
Sokolow index/LVWT 
(cut off ≤ 1.230769) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
65.00% 
64.00%   
1.8 
0.5 
 
 
65.00% 
71.43% 
2.7 
0.4 
 
 
73.33% 
64.00%   
2.0 
0.4 
 
 
73.33% 
71.43% 
2.6 
0.4 
 
 
40.00% 
64.00% 
1.1 
0.9 
 
 
35.00% 
71.43% 
1.2 
0.9 
Sokolow index/(LVWT/h2.7) 
(cut off ≤ 4.300502) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
67.5% 
68% 
2.1 
0.5 
 
 
67.5% 
71.4% 
2.2 
0.4 
 
 
78.3% 
68% 
3.1 
0.4 
 
 
78.3% 
71.4% 
3.3 
0.4 
 
 
35% 
68% 
1.1 
0.9 
 
 
35% 
71.4% 
1.1 
0.8 
Peripheral QRS score/LVMI 
(cut off ≤ 0.2345679) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
73.75% 
73.33% 
2.8 
0.4 
 
 
73.75%   
80.00%   
3.7 
0.3 
 
 
83.33% 
73.33% 
3.1 
0.2 
 
 
83.33% 
80.00% 
4.2 
0.2 
 
 
45.00% 
73.33% 
1.7 
0.8 
 
 
45.00% 
80.00% 
2.3 
0.7 
Peripheral QRS score/LVWT (cut 
off ≤ 2.56) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
72.50% 
72.00% 
2.6 
0.4 
 
 
72.50% 
77.14% 
3.2 
0.4 
 
 
80.00% 
72.00% 
3.6 
0.4 
 
 
81.67% 
77.14% 
3.6 
0.2 
 
 
45.00% 
72.00% 
1.6 
0.8 
 
 
45.00% 
80.00% 
2.3 
0.7 
Peripheral QRS score/(LVWT/h2.7) 
(cut off ≤ 9.01952) 
- Sensitivity 
 
 
76.3% 
 
 
76.3% 
 
 
86.7% 
 
 
86.7% 
 
 
45% 
 
 
45% 
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- Specificity 
- LR+ 
- LR- 
76% 
3.2 
0.3 
82.9% 
3.5 
0.2 
76 % 
5.7 
0.3 
82.9% 
6.2 
0.2 
76% 
1.4 
0.5 
82.9% 
1.5 
0.4 
Total QRS score/LVMI 
(cut off ≤ 0.6950323) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
76.25% 
72.00% 
2.7 
0.3 
 
 
75.00% 
80.00% 
3.8 
0.3 
 
 
81.67% 
72.00% 
2.9 
0.3 
 
 
80.00% 
80.00% 
4.0 
0.3 
 
 
60.00% 
72.00% 
2.1 
0.6 
 
 
55.00% 
80.00% 
2.8 
0.6 
Total QRS score/LVWT 
(cut off ≤ 7.769231) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
78.75% 
78.77% 
3.7 
0.3 
 
 
77.50% 
88.57% 
6.8 
0.3 
 
 
85.00% 
78.77% 
4.0 
0.2 
 
 
83.33% 
88.57% 
7.3 
0.2 
 
 
60.00% 
78.67% 
2.8 
0.5 
 
 
50.00% 
88.57%    
4.4 
0.6 
Total QRS score/(LVWT/h2.7)  
(cut off ≤ 27.32028) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
 
76.3% 
74.7% 
3.1 
0.3 
 
 
 
76.3% 
85.7% 
3.6 
0.2 
 
 
 
85% 
74.7% 
5 
0.3 
 
 
 
85% 
85.7% 
5.7 
0.2 
 
 
 
50% 
74.7% 
1.5 
0.5 
 
 
 
50% 
85.7% 
1.7 
0.3 
LR+ =positive likelihood ratio; LR- =negative likelihood ratio; AC=amyloidotic 
cardiomyopathy; HCM=hypertrophic cardiomyopathy; HHD=hypertensive heart disease; 
AL=light chain-related amyloidosis; CSA=cross sectional area; ED-IVS=end diastolic 
interventricular septum; LV=left ventricular; LVH=LV hypertrophy; LVMI=body surface area 
indexed LV mass; LVWT=LV wall thickness; h=height. 
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Table 4a. Diagnostic performance of the different indices for the identification of AC in a 
population of 200 consecutive male patients with increased LV wall thickness due to either AC, 
HCM or HHD. 
 AC vs. other 
(HCM+HHD) 
AC vs. 
HCM 
AL vs. other 
(HCM+HHD) 
AL vs. 
HCM 
TTR vs. other 
(HCM+HHD) 
TTR vs. 
HCM 
Sokolow index/CSA of LV wall 
(8)  (cut off ≤ 1.2479) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
65.12%  
92.36%  
8.5 
0.4 
 
 
65.12% 
80.43% 
3.3 
0.4 
 
 
61.90% 
92.36%  
8.1 
0.4 
 
 
61.90% 
80.43% 
3.9 
0.5 
 
 
68.18% 
92.99% 
9.7 
0.3 
 
 
68.18% 
82.61% 
3.9 
0.4 
Peripheral QRS score/LVMI 
(cut off ≤0.205725) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
72.09% 
82.80% 
4.2 
0.3 
 
 
72.09% 
71.74% 
2.6 
0.4 
 
 
66.67% 
82.80% 
3.9 
0.4 
 
 
66.67% 
71.74% 
2.4 
0.5 
 
 
77.27% 
82.80% 
4.5 
0.3 
 
 
77.27% 
71.74% 
2.7 
0.3 
Peripheral QRS score/LVWT 
(cut off ≤ 2.37037) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
69.77% 
90.45% 
7.3 
0.3 
 
 
69.77% 
69.57% 
2.3 
0.4 
 
 
57.14% 
90.45% 
5.9 
0.5 
 
 
57.14% 
69.57%   
1.9 
0.6 
 
 
81.82% 
90.45% 
8.6 
0.2 
 
 
81.82% 
69.57% 
2.7 
0.3 
Total QRS score/LVMI 
(cut off ≤ 0.7174721) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
69.77% 
67.52%  
2.1 
0.5 
 
 
67.44% 
78.26% 
3.1 
0.4 
 
 
61.90% 
67.52% 
1.9 
0.6 
 
 
57.14% 
78.26% 
2.6 
0.5 
 
 
77.27% 
67.52% 
2.4 
0.3 
 
 
77.27% 
80.43% 
3.9 
0.3 
Total QRS score/LVWT 
(cut off ≤ 8.357142) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
69.77% 
80.89% 
3.7 
0.4 
 
 
69.77% 
76.09% 
2.9 
0.4 
 
 
71.43% 
80.89% 
3.7 
0.4 
 
 
71.43% 
76.09%  
3.7 
0.4 
 
 
68.18% 
80.89% 
3.6 
0.4 
 
 
68.18% 
76.09% 
2.8 
0.4 
Total QRS score/(LVWT/h2.7) 
(cut off ≤ 36.40046) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
74.4% 
80.9% 
3.2 
0.3 
 
 
74.4% 
78.3% 
3.1 
0.3 
 
 
71.4% 
80.9% 
2.8 
0.3 
 
 
71.4% 
78.3% 
2.7 
0.3 
 
 
77.3% 
80.9% 
3.6 
0.2 
 
 
77.3% 
78.3% 
3.4 
0.3 
LR+ =positive likelihood ratio; LR- =negative likelihood ratio; AC=amyloidotic 
cardiomyopathy; HCM=hypertrophic cardiomyopathy; HHD=hypertensive heart disease; 
AL=light chain-related amyloidosis; CSA=cross sectional area; ED-IVS=end diastolic 
interventricular septum; LV=left ventricular; LVMI=body surface area indexed LV mass; 
LVWT=LV wall thickness; h=height. 
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Table 4b. Diagnostic performance of the different indices for the identification of AC in a 
population of 98 consecutive female patients with increased LV wall thickness due to either AC, 
HCM or HHD. 
 AC vs. other 
(HCM+HHD) 
AC vs. 
HCM 
AL vs. other 
(HCM+HHD) 
AL vs. 
HCM 
TTR vs. other 
(HCM+HHD) 
TTR vs. 
HCM 
Sokolow index/CSA of LV wall (8)  
(cut off ≤ 1.1753) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
68.42%  
92.41% 
9 
0.3 
 
 
68.42% 
71.43% 
2.4 
0.4 
 
 
88.89% 
93.67% 
14 
0.2 
 
 
88.89% 
76.19% 
3.7 
0.1 
 
 
60.00% 
91.14% 
6.8 
0.4 
 
 
50.00% 
71.43% 
1.8 
0.7 
Peripheral QRS score/LVMI 
(cut off ≤ 0.2345679) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
63.16% 
79.75% 
3.1 
0.5 
 
 
63.16% 
90.48% 
6.6 
0.4 
 
 
77.78% 
79.75% 
3.8 
0.3 
 
 
77.78% 
90.48% 
8.2 
0.9 
 
 
50.00% 
79.75% 
2.5 
0.6 
 
 
50.00% 
90.48% 
5.3 
0.6 
Peripheral QRS score/LVWT 
(cut off ≤ 2.56) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
68.42% 
94.94% 
13.5 
0.3 
 
 
63.16% 
90.48% 
6.6 
0.4 
 
 
88.89% 
94.94% 
17.6 
0.1 
 
 
77.78% 
95.24% 
16.3 
0.2 
 
 
50.00% 
94.94% 
9.9 
0.5 
 
 
50.00% 
95.24% 
10.5 
0.5 
Peripheral QRS score/(LVWT/h2.7)  
(cut off ≤ 9.01952) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
68.4% 
96.2% 
3.1 
0.06 
 
 
68.4% 
85.7% 
2.7 
0.2 
 
 
88.9% 
96.2% 
8.7 
0.04 
 
 
88.89% 
85.7% 
7.7 
0.2 
 
 
50%  
96.2% 
1.9 
0.8 
 
 
50%  
85.7% 
1.7 
0.3 
Total QRS score/LVMI 
(cut off ≤ 0.6950323) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
63.16% 
67.09% 
1.9 
0.5 
 
 
63.16% 
80.95% 
3.3 
0.5 
 
 
77.78% 
68.35% 
2.5 
0.3 
 
 
66.67% 
80.95% 
3.5 
0.8 
 
 
50.00% 
67.09% 
1.5 
0.7 
 
 
50.00% 
80.95% 
2.6 
0.6 
Total QRS score/LVWT 
(cut off ≤ 7.769231) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
63.16% 
84.81% 
4.2 
0.4 
 
 
63.16% 
85.71% 
4.4 
0.4 
 
 
77.78% 
84.81% 
5.1 
0.3 
 
 
77.78% 
85.71% 
5.4 
0.3 
 
 
50.00% 
84.81% 
3.3 
0.6 
 
 
50.00% 
85.71% 
3.5 
0.6 
Total QRS score/(LVWT/h2.7)   
(cut off ≤ 27.32028) 
- Sensitivity 
- Specificity 
- LR+ 
- LR- 
 
 
63.2% 
89.9% 
2.4 
0.2 
 
 
63.2% 
81% 
2.2 
0.3 
 
 
77.8% 
89.9% 
4.4 
0.1 
 
 
77.8% 
81% 
3.6 
0.2 
 
 
50% 
89.9% 
1.8 
0.2 
 
 
50% 
81% 
1.6 
0.4 
LR+ =positive likelihood ratio; LR- =negative likelihood ratio; AC=amyloidotic 
cardiomyopathy; HCM=hypertrophic cardiomyopathy; HHD=hypertensive heart disease; 
AL=light chain-related amyloidosis; CSA=cross sectional area; ED-IVS=end diastolic 
interventricular septum; LV=left ventricular; LVMI=body surface area indexed LV mass; 
LVWT=LV wall thickness; h=height. 
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Table 5a. Diagnostic performance of the different indices for the identification of AC for the 
entire population of male patients with different causes of increased LV wall thickness (n=514) 
in the different clinical settings.  
AC vs other (HCM+HHD) 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 44% 91% 72% 8% 74% 68% 68% 76% 74% 73% 78% 77% 78% 
Spec 93% 27% 83% 100% 80% 84% 83% 80% 83% 82% 72% 79% 81% 
LR+ 6.6 1.3 3.0 . 3.0 2.7 2.6 3.3 3.2 3.1 3.4 3.4 3.6 
LR- 0.6 0.3 0.2 0.9 0.3 0.2 0.3 0.3 0.2 0.2 0.3 0.3 0.2 
AC vs HCM 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 44% 91% 72% 8% 74% 68% 68% 75% 74% 73% 78% 77% 78% 
Spec 96% 61% 76% 99% 74% 78% 79% 76% 73% 72% 81% 80% 85% 
LR+ 10.2 2.3 2.8 9.4 2.8 2.5 2.5 3.1 2.8 2.7 3.7 3.4 3.8 
LR- 0.6 1.2 0.3 0.9 0.4 0.3 0.3 0.3 0.4 0.4 0.2 0.3 0.2 
AL vs other (HCM+HHD) 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 57% 90% 77% 12% 79% 75% 75% 79% 80% 77% 815 82% 83% 
Spec 93% 27% 83% 100% 80% 84% 83% 80% 83% 82% 73% 79% 81% 
LR+ 8.6 1.2 3.6 . 3.7 3.3 3.3 3.8 4.1 3.6 3.9 4.4 4.7 
LR- 0.5 0.4 0.2 0.9 0.3 0.2 0.2 0.3 0.2 0.2 0.3 0.3 0.2 
AL vs HCM 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 57% 90% 77% 12% 79% 75% 75% 79% 80% 77% 81% 82% 83% 
Spec 96% 61% 76% 99% 74% 78% 79% 77% 73% 72% 81% 80% 85% 
LR+ 13.2 2.3 3.3 13.4 3.5 3.1 3.1 3.6 3.6 3.1 4.3 4.4 4.9 
LR- 0.5 0.2 0.3 0.9 0.3 0.3 0.3 0.3 0.3 0.4 0.2 0.3 0.2 
 TTR vs other (HCM+HHD) 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 28% 91% 67% 4% 68% 61% 60% 72% 67% 69% 75% 71% 72% 
Spec 93% 27% 83% 100% 80% 84% 83% 80% 83% 78% 73% 79% 81% 
LR+ 4.3 1.3 2.5 . 2.5 2.2 2.1 2.9 2.5 2.7 2.9 2.7 2.9 
LR- 0.8 0.3 0.3 1 0.3 0.3 0.3 0.3 0.3 0.3 0.4 0.3 0.3 
TTR vs HCM 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 28% 91% 67% 4% 68% 61% 60% 71% 67% 69% 75% 71% 72% 
Spec 96% 61% 76% 99% 74% 78% 79% 76 73% 72% 81% 80% 85% 
LR+ 6.6 2.3 2.3 4.5 2.3 2 2 2.6 2.2 1.7 3.2 2.7 3.0 
LR- 0.8 0.1 0.4 1 0.4 0.4 0.4 0.3 0.4 0.3 0.3 0.3 0.2 
32 
 
LQV=low QRS voltage; Symm. LVH=symmetric left ventricular hypertrophy; Sens.=sensitivity; 
Spec.=specificity; LR+ =positive likelihood ratio; LR- =negative likelihood ratio; 
AC=amyloidotic cardiomyopathy; HCM=hypertrophic cardiomyopathy; HHD=hypertensive 
heart disease; AL=light chain-related amyloidosis; LVMI=body surface area indexed left 
ventricular mass; LVWT= left ventricular wall thickness, pQRS=peripheral QRS score;  
tQRS=total QRS score. 
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Table 5b. Diagnostic performance of the different indices for the identification of AC for the 
entire population of female patients with different causes of increased LV wall thickness (n=253) 
in the different clinical settings. 
AC vs other (HCM+HHD) 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 52% 91% 68% 5% 68% 65% 68% 72% 73% 75% 75% 76% 74% 
Spec 91% 23% 81% 100% 80% 77% 81% 76% 83% 86% 69% 81% 83% 
LR+ 5.7 1.2 2.7 . 2.5 2.2 2.5 2.7 3.0 3.4 2.7 3.3 3.1 
LR- 0.5 0.4 0.3 0.9 0.3 0.4 0.3 0.3 0.2 0.2 0.4 0.3 0.2 
AC vs HCM 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 52% 91% 70% 5% 68% 65% 68% 72% 73% 75% 75% 76% 74% 
Spec 95% 59% 71% 100% 71% 68% 71% 82% 82% 84% 80% 86% 84% 
LR+ 9.6 2.2 2.4 . 2.2 1.9 2.2 2.9 3.0 3.3 3.2 3.5 3.2 
LR- 0.5 0.2 0.4 0.9 0.4 0.5 0.4 0.2 0.2 0.2 0.3 0.2 0.2 
AL vs other (HCM+HHD) 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 64% 87% 77% 4% 78% 62% 80% 83% 84% 87% 81% 84% 84% 
Spec 91% 23% 81% 100% 80% 70% 81% 76% 83% 86% 69% 81% 83% 
LR+ 7.0 1.1 3.5 . 3.7 3 4 4.4 5.2 6.6 3.7 5.1 5.2 
LR- 0.4 0.6 0.3 1 0.3 0.3 0.2 0.3 0.2 0.2 0.4 0.2 0.2 
AL vs HCM 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 64% 87% 77% 4% 78% 74% 80% 83% 84% 87% 81% 84% 84% 
Spec 95% 59% 71% 100% 71% 68% 71% 82% 82% 84% 80% 86% 84% 
LR+ 11.9 2.1 3.1 . 3.3 2.6 3.5 4.7 5.2 6.4 4.3 5.4 5.3 
LR- 0.4 0.2 0.4 1 0.4 0.4 0.4 0.2 0.2 0.2 0.2 0.2 0.2 
 TTR vs other (HCM+HHD) 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 23% 100% 53% 7% 43% 43% 40% 47% 47% 47% 60% 57% 50% 
Spec 91% 23% 81% 100% 80% 77% 81% 76% 83% 86% 69% 81% 83% 
LR+ 2.6 1.3 1.7 . 1.4 1.4 1.3 1.4 1.6 1.6 1.7 1.9 1.7 
LR- 0.8 0 0.4 0.9 0.5 0.5 0.5 0.5 0.4 0.3 0.5 0.2 0.4 
TTR vs HCM 
 LQV Symm.  
LVH 
Carrol 
index  
Rahman 
index 
Sokolow 
/ 
LVMI 
Sokolow 
/ 
LVWT 
Sokolow 
/ 
(LVWT 
/h2.7) 
pQRS 
/ 
LVMI 
pQRS 
/ 
LVWT 
pQRS 
/ 
(LVWT 
/h2.7) 
tQRS 
/ 
LVMI 
tQRS 
/ 
LVWT 
tQRS 
/ 
(LVWT 
/h2.7) 
Sens 23% 100% 53% 7% 43% 43% 40% 47% 47% 47% 60% 57% 50% 
Spec 95% 59% 71% 100% 71% 68% 71% 82% 82% 84% 80% 86% 84% 
LR+ 4.4 2.4 1.5 . 1.3 1.2 1.2 1.5 1.5 1.6 2.0 2 1.7 
LR- 0.8 0 0.5 0.9 0.7 0.7 0.7 0.4 0.4 0.3 0.3 0.3 0.3 
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LQV=low QRS voltage; Symm. LVH=symmetric left ventricular hypertrophy; Sens.=sensitivity; 
Spec.=specificity; LR+ =positive likelihood ratio; LR- =negative likelihood ratio; 
AC=amyloidotic cardiomyopathy; HCM=hypertrophic cardiomyopathy; HHD=hypertensive 
heart disease; AL=light chain-related amyloidosis; LVMI=body surface area indexed left 
ventricular mass; LVWT= left ventricular wall thickness, pQRS=peripheral QRS score; 
tQRS=total QRS score; h=height. 
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Table 6. Studies dedicated to the diagnostic role of ECG in cardiac amyloidosis 
Study No. of patients with cardiac 
amyloidosis 
Controls Proposed 
criteria 
Diagnostic 
performance 
No. AL TTR No. Cardiac 
disease 
Normal  
Carrol JD,  
Am J Cardiol 
1982
8
 
14 14 0 32 24 aortic 
valve 
disease, 8 
pericardial 
effusion 
0 Sokolow 
index/cross 
sectional area 
of LV wall 
Inverse correlation 
between voltage and 
LV wall thickness 
in AC 
Dubrey SW, 
QJM 1998
6
 
232 232 0 0 0 0 / Low QRS voltage in 
70-74% of patients 
Rahman JE,  
JACC 2004
9
  
58 (8 also 
with 
myocarditis), 
24 with 
congo-red 
stain but 
without any 
immunohisto-
chemical 
stains 
7 4 138 - 22 
myocarditis, 
66/35 
myocyte 
hypertrophy 
with/without 
fibrosis, 15 
nonspecific 
findings 
0 Low QRS 
voltage + 
end-diastolic 
IVS 
thickness > 
1.98 cm 
Sensitivity=72% 
Specificity=91% 
PPV=79% 
NPV=88% 
Murtagh B,  
Am J Cardiol 
2005
7
 
127 127 0 0 0 0 ECG and 
ECHO 
findings 
Weak inverse 
correlation between 
low voltage and 
PW/IVS 
Hoignè Ph,  
Int J Cardiol 
2006
26
 
16 ? ? 52 22 HHD, 13 
Fabry 
disease, 17 
HCM 
0 Combination 
of symptoms, 
ECG and 
ECHO in 
unexplained 
LVH 
/ 
Piper C,  
Amyloid 
2010
27
 
30 25 5  
(ATTRwt) 
0 0 0 ECG (low 
QRS voltage, 
poor R wave 
progression) 
+ ECHO 
(TDI, strain 
imaging) 
Proposed criteria for 
the evaluation of pts 
with heart failure of 
unknown origin 
Cheng Z,  
Ann 
Noninvasive 
Electrocardiol 
2011
10
 
11 11 0 9 7/2 myocyte 
hypertrophy 
with/without 
fibrosis 
0 - Sv1+R v6 
- R 
v1/LVPW<0.4 
- R 
v6/LVPW<0.7 
- 
Sens/Spec=91/89% 
- 
Sens/Spec=91/100% 
- 
Sens/Spec=91/89% 
Namdar M,  
Am J Cardiol 
2012
28
 
17  ? ? 77 20 HHD, 17 
Fabry 
disease, 20 
AS, 20 
HCM 
0 QTc > 440 
msec + 
Sokolow-
Lyon index ≤ 
1.5 mV   
Sensitivity=85% 
Specificity=100% 
 
AC=amyloidotic cardiomyopathy; HCM=hypertrophic cardiomyopathy; HHD=hypertensive 
heart disease; AS=aortic stenosis; LV=left ventricle; ECHO=echocardiographic; LVH=left 
ventricular hypertrophy; PPV=positive predictive value; NPV=negative predictive value; 
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Sens=sensitivity; Spec=specificity; PW=posterior wall; IVS=interventricular septum; AL=light 
chain amyloidosis; TTR=Transthyretin amyloidosis; ATTRwt=wild-type transthyretin-related 
amyloidosis. 
 
37 
 
Figure 1.  
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Figure 2.  
a) 
 
b) 
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Figure 3. 
a) 
 
b) 
 
